All
Combining Old and New Therapies in Advanced Bladder Cancer Shows Promise for the Future
September 29th 2022As part of its “Speaking Out” video series, CURE spoke with Dr. Tracy L. Rose, on behalf of the Bladder Cancer Advocacy Network, about how currently available agents are being investigated in combination with one another.
Early-Phase Trial to Study Novel Drug, With or Without Keytruda, in Solid Cancers
September 27th 2022The novel drug PY159 will be studied as a single agent and in combination with Keytruda for patients with certain solid tumors — including ovarian, pancreatic, lung, head and neck, colorectal and breast cancers.
Phase 3 Trial to Study an Immunochemotherapy Regimen in Platinum-Resistant/Refractory Ovarian Cancer
September 26th 2022The OnPrime trial will investigate if adding Olvi-Vec, a modified virus, to chemotherapy and Avastin will improve outcomes for pretreated platinum-resistant or refractory ovarian cancer.
The power of a strong doctor-patient partnership and positivity when fighting lymphoma
September 26th 2022Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) cancer survivor Louise (left) and her oncologist, Dr. Ruemu Birhiray (right), built a lasting relationship as they navigated Louise’s diagnosis and relapse. This article is sponsored by MorphoSys and Incyte.
When Cancer Treatment Leads to a Secondary Cancer: Survivor Shares Her Story of Angiosarcoma
September 23rd 2022Seven years after completing breast cancer treatment, Angelia Carpenter was shocked to discover she had angiosarcoma, a rare cancer that may have been associated with her breast cancer treatment.
Blood Test Results May Offer Clues to Neurotoxicity Risk After CAR-T Cell Therapy in Cancer
September 22nd 2022Patients with blood cancer who have higher levels of neurofilament light chains — which indicate brain injury — were found to be more likely to develop neurotoxicity after CAR-T cell therapy, according to recent research.